The following is the indication of Reslizumab?
**Core Concept**
Reslizumab is a monoclonal antibody that targets interleukin-5 (IL-5), a cytokine involved in the pathogenesis of severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA). By binding to IL-5, Reslizumab reduces eosinophilic inflammation and improves symptoms in patients with severe asthma and EGPA.
**Why the Correct Answer is Right**
Reslizumab specifically targets IL-5, which promotes the survival and activation of eosinophils. By inhibiting IL-5, Reslizumab reduces eosinophilic inflammation, leading to improved lung function and reduced symptoms in patients with severe asthma and EGPA. The mechanism of action is mediated through the IL-5 receptor, which is expressed on the surface of eosinophils.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it is not a known indication of Reslizumab. While Reslizumab does target IL-5, its use is specifically approved for severe asthma and EGPA, not for other conditions.
**Option B:** This option is incorrect because it is not a correct indication of Reslizumab. While asthma is a correct indication, the specific mention of "oral corticosteroid-dependent" is not a characteristic feature of Reslizumab's approved use.
**Option C:** This option is incorrect because it is not a specific indication of Reslizumab. While Reslizumab does target IL-5, its use is specifically approved for severe asthma and EGPA, not for a broad range of conditions.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that Reslizumab is specifically approved for use in patients with severe asthma and EGPA who have a high eosinophil count and are not adequately controlled with standard treatments. This highlights the importance of identifying patients with eosinophilic asthma and EGPA, who may benefit from targeted therapies like Reslizumab.
**Correct Answer: D. Severe asthma with an eosinophilic phenotype.**